Eliaz Therapeutics
Santa Rosa, US · Founded 2015 · California corporation
Eliaz Therapeutics develops XGal-3, an investigational therapeutic apheresis device that uses an antibody-based resin to remove the protein Galectin-3 from the bloodstream. It targets Galectin-3 as a driver of sepsis, cancer, heart disease, fibrosis, and kidney disease, and is in the preclinical and first-in-human study stage.
Founders & leadership
Eliaz Therapeutics was founded in 2015 by Isaac Eliaz.
Funding
SEC filings, press & company announcements$2.9M disclosed across 2 of 3 rounds · 2016–2026
- Undisclosed amountRegulation Crowdfunding (Reg CF) investment roundJun 2026Source ↗
▶$850KraisedOct 2025 · 4 investors · BiotechnologyRule 506(b)
- Isaac EliazExecutive Officer, Director
- Milton GossExecutive Officer
- Offering amount
- $850K
- Amount sold
- $850K
- Minimum investment
- $100K
- Proceeds to insiders
- $50K
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedNov 2016 · 1 investors · Other Health CareRule 506(b)
- Isaac EliazExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- Minimum investment
- $1M
- First sale
- Nov 2016
- Incorporated
- Corporation, California, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Companies competing with Eliaz Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $224.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Eliaz Therapeutics do?
- Eliaz Therapeutics develops XGal-3, an investigational therapeutic apheresis device that uses an antibody-based resin to remove the protein Galectin-3 from the bloodstream. It targets Galectin-3 as a driver of sepsis, cancer, heart disease, fibrosis, and kidney disease, and is in the preclinical and first-in-human study stage.
- Who founded Eliaz Therapeutics?
- Eliaz Therapeutics was founded by Isaac Eliaz in 2015.
- How much funding has Eliaz Therapeutics raised?
- Eliaz Therapeutics has disclosed $2.9M raised across 2 of its 3 known rounds.
- Where is Eliaz Therapeutics headquartered?
- Eliaz Therapeutics is headquartered in Santa Rosa, US.